期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

SPARC及白蛋白结合型紫杉醇在非小细胞肺癌中的进展 被引量：7

Progress of SPARC and nab-paclitaxel in non-small-cell lung cancer
原文传递
导出
摘要 SPARC是一种多功能糖蛋白,有3个生物学功能区,能被蛋白水解酶降解成不同肽段,产生不同的生物学效应,破坏局部黏着复合物,产生抗黏附作用,调节细胞周期,在肿瘤的发生进展过程中起了重要作用。白蛋白结合型紫杉醇是一种新型的紫杉醇类药物,与溶剂型紫杉醇相比,它疗效更高且不良反应减轻,一些研究发现SPARC可能与白蛋白结合型紫杉醇疗效有关,本文就SPARC和白蛋白结合型紫杉醇在非小细胞肺癌中的研究现状作一综述。 SPARC is a multifunctional glycoprotein which has three biological structural domains. SPARC can be degraded by proteolytic enzymes into different peptides, resulting in different biological effects, such as inducing focal adhesion disassembly, exhibiting an antiadhesive function and regulating cell cycle. SPARC plays an important role in the development of various tumors. Nab-paclitaxel is a new type of paclitaxel and has a better effect and less adverse reactions compared with solvent-based paclitaxel. It’s found that the effect of nab-paclitaxel may correlate with SPARC. This review had a brief introduction to the development of SPARC and nab-paclitaxel in non-small cell lung cancer.
作者 郑鹏凤 韩福才 郭沁香 王静 单彬彬 张帆
机构地区 山西医科大学第二临床医学院 山西省肿瘤医院呼吸一科
出处 《中华临床医师杂志（电子版）》 CAS 2016年第14期2136-2140,共5页 Chinese Journal of Clinicians(Electronic Edition)
关键词 癌 非小细胞肺 SPARC 白蛋白结合型紫杉醇 Carcinoma non-small-cell lung SPARC Nab-paclitaxel
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1Koukourakis Michael I,Giatromanolaki Alexandra,Brekken Rolf A,Sivridis Efthimios,Gatter Kevin C,Harris Adrian L,Sage E Helene.Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Research . 2003
  • 2Liu ZF,Wei ZM,Hu Y,et al.A phaseⅡopen-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stageⅢB/Ⅳnon-small-cell lung cancer. Medical Oncology . 2015
  • 3Von Hoff DD,Ramanathan RK,Borad MJ,et al.Gemcitabine plusnab-paclitaxel is an active regimen inpatients with advanced pancreatic cancer:A phaseⅠ/ⅡTrial. Journal of Clinical Oncology . 2011
  • 4Nie, Jing,Helene Sage, E.SPARC inhibits adipogenesis By its enhancement of β-catenin signaling. Journal of Biological Chemistry . 2009
  • 5Tang, Michelle J.,Tai, Isabella T.A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. Journal of Biological Chemistry . 2007
  • 6Rahman M,Chan AP,Tai IT.Apeptide of SPARC interferes with theinteraction between caspase-8and Bcl-2to resensitize chemoresistanttumors and enhance their regression in vivo. PLoS One . 2011
  • 7Kurtul N,Eroglu C,Unal D,et al.Prognostic value of SPARC expression in unresectable NSCLC treated with concurrent chemoradiotherapy. Asian Pacific Journal of Cancer Prevention . 2014
  • 8Brat D J,Windebank A J,Brimijoin S.Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. The Journal of pharmacology and experimental therapeutics . 1992
  • 9Sparreboom Alex,Scripture Charity D,Trieu Vuong,Williams Paul J,De Tapas,Yang Andrew,Beals Bridget,Figg William D,Hawkins Michael,Desai Neil.Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clinical cancer research : an official journal of the American Association for Cancer Research . 2005
  • 10Hanrui Chen,Xuewu Huang,Shutang Wang,Xinting Zheng,Jietao Lin,Peng Li,Lizhu Lin.Nab-paclitaxel(abraxane)-based chemotherapy to treat elderly patients with advanced non-small-cell lung cancer:a single center,randomized and open-label clinical trial[J].Chinese Journal of Cancer Research,2015,27(2):190-196. 被引量：12

二级参考文献77

  • 1Podhajcer OL, Benedetti LG, Girotti MR, et a\. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev, 2008,27:691- 705.
  • 2Brekken RA, Sage EH. SPARe, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Bioi, 2001,19: 816-827.
  • 3Arnold SA, Brekken RA. SPARe: a matricellular regulator of tumorigenesis. J Cell Commun Signal, 2009,3:255-723.
  • 4Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest, 2001,107: 1049-1054.
  • 5Chlenski A, Cohn SL. Modulation of matrix remodeling by SP ARC in neoplastic progression. Semin Cell Dev Bioi, 2010,21 :55-65.
  • 6Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat, 2008,11 :231-246.
  • 7Chin D, Boyle G M, Williams RM, et al. Novel markers for poor prognosis in head and neck cancer. Int J Cancer, 2005,113: 789-797.
  • 8Miyoshi K, Sato N, Ohuchida K, et al. SPARC mRNA expression as a prognostic marker for pancreatic aceno?carci noma patients. Anticancer Res, 2010,30: 867 - 871 .
  • 9Zhao ZS, Wang YY, Chu YQ, et al. SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res, 2010,16:260-268.
  • 10Said N, Socha MJ, Olearczyk JJ, et a'. Normalization ot the ovarian cancer microenvironment by SPARG. Mol Cancer Res, 2007,5: 1015-1030.

共引文献33

同被引文献57

引证文献7

二级引证文献41

中华临床医师杂志（电子版）
2016年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部